首頁 > 市場調查報告書 > 製藥

神經疾病孤兒藥

市場調查報告書

商品編碼

2039013

Deutetrabenazine市場：依適應症、劑型、最終用戶、通路及地區分類

Deutetrabenazine Market, By Indication, By Formulation Type, By End User, By Distribution Channel, By Geography

出版日期: 2026年04月06日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，Deutetrabenazine市場價值將達到 10.8 億美元，到 2033 年將達到 18.8 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 8.24%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	10.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.24%	2033年市場規模預測：	18.8億美元

Deutetrabenazine被認為是治療亨丁頓舞蹈症和遲發性運動障礙等人類神經運動疾病的重大治療進展。

Deutetrabenazine作為一種選擇性囊泡單胺轉運蛋白2 (VMT2) 抑制劑，已被證實具有療效，與其他藥物（如Tetrabenazine）相比，它具有更優的療效、耐受性和更低的副作用發生率。Deutetrabenazine的問世增強了針對運動過度症的標靶治療選擇，滿足了先前一些未被滿足的醫療需求。因此，人們對罕見神經系統疾病的認知不斷提高，診斷方法也取得了進步，導致確診患者人數增加。

鑑於孤兒藥療法和精準醫療的研發日益受到重視，全球Deutetrabenazine市場可被視為神經系統治療領域的重要細分市場。該市場提供多種劑型和劑量，以滿足不同患者群體的需求。包括核准情況、醫療基礎設施的進步、醫生認知度的提高以及患者用藥途徑的改善在內的多種因素都在影響著該市場。這些因素共同推動了該藥物作為運動障礙核心治療方案的企業發展。

市場動態

全球Deutetrabenazine市場的主要驅動力是亨廷頓舞蹈症和遲發性運動障礙盛行率的上升，以及基因檢測和神經系統評估技術的進步帶來的診斷方法改進。此外，醫療專業人員對Deutetrabenazine作為第一線治療藥物的療效認知不斷提高，也是推動Deutetrabenazine市場成長的因素之一。

已開發國家的健保政策推動了Deutetrabenazine使用量的增加。越來越多的臨床證據顯示其安全性良好，且與其他治療方法相比，Deutetrabenazine的使用頻率不斷提高，從而改善了治療效果，提高了患者遵守用藥，進而推動了全球Deutetrabenazine市場的成長。

儘管存在這些優勢，市場仍面臨許多挑戰。例如，高昂的治療費用限制了價格敏感市場和開發中國家的可近性。此外，基層醫療醫師對罕見神經系統疾病的認知不足，以及運動障礙診斷的難度，都限制了治療的啟動速度。罕見疾病患者數量少以及嚴格的監管也限制了市場滲透的速度。

然而，鑑於新興市場醫療基礎設施的不斷完善和醫療支出的持續成長，市場成長機會巨大。預計未來市場創新將成為推動市場成長的主要動力。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球Deutetrabenazine市場的主要參與者進行了分析：公司亮點、產品系列、主要特徵、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球Deutetrabenazine市場報告的目標受眾是該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過對全球Deutetrabenazine市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

Teva Pharmaceutical Industries
Neurocrine Biosciences
Bausch Health Companies
Lundbeck
Intas Pharmaceuticals
Upsher Smith Laboratories
Reddy's Laboratories
Lupin
Apotex
Viatris

第10章分析師建議

機會
分析師意見
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9419

Deutetrabenazine Market is estimated to be valued at USD 1.08 Bn in 2026 and is expected to reach USD 1.88 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.24% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.08 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.24%	2033 Value Projection:	USD 1.88 Bn

Deutetrabenazine has been identified as a major therapeutic advancement in the management of human neurological movement disorders such as Huntington's disease and tardive dyskinesia.

Deutetrabenazine has shown efficacy in its use as a selective inhibitor of the vesicular monoamine transporter 2, offering better efficacy and tolerability at a reduced frequency compared to other drugs such as tetrabenazine. The introduction of deutetrabenazine has reinforced the armamentarium of targeted therapies for the management of hyperkinetic movement disorders, meeting some of the hitherto unmet clinical needs. As a result, the growing awareness of rare neurological disorders, along with improvements in diagnostic methods, has led to an increase in the number of patients diagnosed.

The global deutetrabenazine market can be considered a significant niche market for the neurology therapeutics segment, with the growing emphasis on the development of orphan drug therapies and precision medicine. The market is served by various formulations and strengths of the drug to address the different needs of the patient population. Various factors affect the market, including approvals, advances in healthcare infrastructure, awareness among physicians, and improved patient access programs. These factors contribute to the business development of the drug as a backbone treatment option for movement disorders.

Market Dynamics

The global deutetrabenazine market is primarily driven by the rise in the prevalence of Huntington's disease and tardive dyskinesia, and the improvement in diagnostic methods due to better genetic testing and neurological assessment methods. The rise in awareness among medical professionals about the effectiveness of deutetrabenazine as a first-line treatment for patients is driving the global deutetrabenazine market.

The increasing use of deutetrabenazine is supplemented by the reimbursement policies of developed countries. The rise in clinical evidence of the safety profile and the frequency of use of deutetrabenazine compared to other treatments is driving the global deutetrabenazine market due to better outcomes and better compliance among patients.

Despite these advantages, the market is facing some challenges, such as the high cost of treatment, which is limiting the market in terms of accessibility in price-sensitive and developing markets. In addition, a lack of awareness of rare neurological disorders among primary care physicians and the difficulty of diagnosing movement disorders are limiting the market in terms of the speed of treatment initiation. The small population of patients with orphan diseases and the stringent regulations are also limiting the market in terms of speed of the market penetration.

However, the opportunities for growth are significant in the context of the emerging markets and the increasing healthcare infrastructure and expenditure in these markets. The innovations in the market are expected to boost the market in the future.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global deutetrabenazine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries, Neurocrine Biosciences, Bausch Health Companies, H. Lundbeck, Intas Pharmaceuticals, Upsher-Smith Laboratories, Dr. Reddy's Laboratories, Lupin, Apotex, and Viatris
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global deutetrabenazine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global deutetrabenazine market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Tardive Dyskinesia (TD)
- Huntington's Disease Chorea
Formulation Type Insights (Revenue, USD Bn, 2021 - 2033)
- Immediate-Release (IR)
- Extended-Release (XR)
End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Teva Pharmaceutical Industries
- Neurocrine Biosciences
- Bausch Health Companies
- Lundbeck
- Intas Pharmaceuticals
- Upsher-Smith Laboratories
- Reddy's Laboratories
- Lupin
- Apotex
- Viatris

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Deutetrabenazine Market, By Indication
- Global Deutetrabenazine Market, By Formulation Type
- Global Deutetrabenazine Market, By End User
- Global Deutetrabenazine Market, By Distribution Channel
- Global Deutetrabenazine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Deutetrabenazine Market, By Indication, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Tardive Dyskinesia (TD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Huntington's Disease Chorea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Deutetrabenazine Market, By Formulation Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Immediate-Release (IR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Extended-Release (XR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Deutetrabenazine Market, By End User, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Deutetrabenazine Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global Deutetrabenazine Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Neurocrine Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bausch Health Companies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Upsher Smith Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lupin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies